A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis
Open Access
- 12 July 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1679
Abstract
Activated factor XI (FXIa) is an important antithrombotic drug target. Clinical and pre-clinical data have demonstrated that its inhibition attenuates thrombosis with minimal risk of excessive bleeding. We isolated Fasxiator from the venom of banded krait Bungarus fasciatus and subsequently engineered FasxiatorN17R,L19E, with improved affinity (Ki = 0.9 nM) and selectivity towards FXIa. Here, we assess the in vivo efficacy and bleeding risk of rFasxiatorN17R, L19E in pre-clinical animal models. Rats injected intravenously (i.v.) with bolus rFasxiatorN17R, L19E showed the specific in vivo attenuation of the intrinsic coagulation pathway, lasting for at least 60 min. We performed the in vivo dose-ranging experiments for rFasxiatorN17R, L19E as follows: FeCl3-induced carotid artery occlusion in rats (arterial thrombosis); inferior vena cava ligation in mice (venous thrombosis); tail bleeding time in both rats and mice (bleeding risk). Head-to-head comparisons were made using therapeutic dosages of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) for arterial and venous thrombosis, respectively. In the arterial thrombosis model, 2 mg/kg i.v. rFasxiatorN17R,L19E achieved a similar antithrombotic efficacy to that of UFH, with >3-fold lower bleeding time. In the venous thrombosis model, the 10 mg/kg subcutaneous (s.c.) injection of rFasxiatorN17R,L19E achieved similar efficacy and bleeding levels to those of LMWH enoxaparin. Overall, rFasxiatorN17R,L19E represents a promising molecule for the development of FXIa-targeting anticoagulants.Keywords
Funding Information
- National Medical Research Council (CIRG17may014, OFYIRG16may021, CG21APR1008)
- National Medical Research Council (CIRG17may014, OFYIRG16may021, CG21APR1008)
- National Medical Research Council (CIRG17may014, OFYIRG16may021, CG21APR1008)
This publication has 52 references indexed in Scilit:
- A Spider-Derived Kunitz-Type Serine Protease Inhibitor That Acts as a Plasmin Inhibitor and an Elastase InhibitorPLOS ONE, 2013
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- Male mice have increased thrombotic potential: Sex differences in a mouse model of venous thrombosisThrombosis Research, 2011
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosisThrombosis and Haemostasis, 2011
- Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasisJournal of Experimental Medicine, 2009
- TSG-6 Potentiates the Antitissue Kallikrein Activity of Inter–α-inhibitor through Bikunin ReleaseAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Effects of factor XI deficiency on ferric chloride‐induced vena cava thrombosis in miceJournal of Thrombosis and Haemostasis, 2006
- Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac arteryJournal of Thrombosis and Haemostasis, 2006
- Characterization of the Interaction between Tumor Necrosis Factor-stimulated Gene-6 and HeparinJournal of Biological Chemistry, 2005
- New anticoagulantsBlood, 2005